Abstract | OBJECTIVES: METHODS: RESULTS: After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63). CONCLUSIONS: Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.
|
Authors | L Mariani, A Sedati, R Giovinazzi, R Sindico, G Atlante |
Journal | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
(Int J Gynaecol Obstet)
Vol. 44
Issue 2
Pg. 155-9
(Feb 1994)
ISSN: 0020-7292 [Print] United States |
PMID | 7911101
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Aged
- Danazol
(administration & dosage)
- Endometrial Hyperplasia
(drug therapy, pathology)
- Endometrium
(pathology)
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Postmenopause
- Recurrence
|